Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Core Viewpoint - Avacta Therapeutics has demonstrated that its proprietary pre|CISION platform offers significant advantages over the marketed antibody drug conjugate (ADC) Enhertu, with plans to initiate a clinical trial for FAP-Exd (AVA6103) in Q1 2026 [1][3]. Group 1: Clinical Data and Comparisons - The analysis compares the delivery profile of pre|CISION FAP-cleavable payload with Enhertu, which is approved for breast and gastric cancer [3]. - The pre|CISION platform shows three key advantages: faster drug penetration into tumors, a higher maximum drug concentration in tumors, and a nearly three-fold higher Tumor Selectivity Index compared to Enhertu [4][9]. - The maximum concentration (Cmax) of FAP-Exd in tumor tissue occurs within minutes, while T-Dxd reaches its maximum concentration at 24 hours [9]. Group 2: Mechanism and Efficacy - The pre|CISION delivery mechanism is designed to selectively deliver potent payloads to tumors while minimizing exposure to normal tissues, enhancing safety and effectiveness [11][13]. - The analysis indicates that FAP-Exd shows higher activity in tumor models with low FAP expression compared to T-Dxd's variable activity at low HER2 expression levels [7]. - Deep and durable responses were observed with FAP-Exd, persisting for weeks after a three-dose regimen [7]. Group 3: Future Plans and Innovations - Avacta plans to present these findings at an upcoming scientific congress and submit them to a peer-reviewed journal [8]. - The use of AI to create a synthetic comparator arm for data analysis highlights the innovative approach of the company's research team [5][6].